Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi to buy biopharmaceutical firm Principia Biopharma for $3.68bn
As per terms of the deal, Sanofi will purchase all of the outstanding shares of Principia by paying $100 per share in cash. Principia Biopharma is engaged in
As per terms of the deal, Sanofi will purchase all of the outstanding shares of Principia by paying $100 per share in cash. Principia Biopharma is engaged in
Niclosamide was recently identified by Institut Pasteur Korea as a potent inhibitor of SARS-CoV-2, the virus causing COVID-191. For a number of years, UNION has worked with niclosamide
The acceptance of IND will allow Enzychem to assess EC-18 in a phase 2 clinical study in patients with ARDS due to Covid-19. The EC-18 is originally obtained
Started in May 2020, BLADE-CONQUER (ClinicalTrials.gov NCT04334460) is a double-blind, placebo-controlled clinical trial assessing the efficacy and safety of BLD-2660 on lung function and recovery time in hospitalized
Both companies have not disclosed the financial terms of the deal. The research will include the application of GeneCentric’s advanced RNA-based molecular profiling platform to illustrate the potential
Today’s award of up to $1.525bn is for the manufacturing and delivery of 100 million doses of mRNA-1273 including incentive payments for timely delivery of the product. With
The acquisition of KaNDy Therapeutics will allow Bayer to expand its drug development pipeline in women’s healthcare. The deal also allows KaNDy Therapeutics to secure potential milestone payments
Appili is expanding its Phase 2 clinical trial into the U.S. to evaluate the safety and efficacy of favipiravir tablets in controlling outbreaks following exposure to COVID-19 in
Under the deal, Ligand Pharmaceuticals will purchase all outstanding shares of Pfenex for $12 per share in cash or $438m in equity value on a fully diluted basis.
Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer’s McPherson, Kansas facility to manufacture and supply remdesivir for Gilead. In March, Pfizer launched